Search company, investor...


Corporate Majority | Acquired

Total Raised


About CMAB Biopharma

CMAB Biopharma is a full-service contract development and manufacturing organization (CDMO) that provides process development and manufacturing services for biologic drug substances and drug products. On March 17, 2021, WuXi Biologics acquired a majority stake in CMAB Biopharma. The terms of the transaction were not disclosed.

Headquarters Location

Bld. C37 No. 188 Dong Ping Road, Suzhou Industry Campus

Suzhou, Jiangsu,


+86 0512-69566088



Latest CMAB Biopharma News

WuXi Biologics completes three acquisitions to expand its global network

May 8, 2021

May 8, 2021 WuXi Biologics, a global company with leading open access biologics technology platforms, announced that it has acquired a Bayer manufacturing facility in Wuppertal, Germany, which has completed Pfizer China (Pfizer) manufacturing facilities in Hangzhou, China and the CMAB Biopharma Group (CMAB). As part of the acquisition agreement signed with Bayer in December 2020, WuXi Biologics has taken over the operation and assets of an active ingredient plant (MFG19) in Wuppertal, which comprises 3 x 1,000L perfusion and 6 x 2,000L fed-batch capacities with independent downstream suites becomes. As announced in March 2021, WuXi Biologics completed the acquisition of the Biological Ingredients and Products (MFG20 / DP9 / DP10) facilities from Pfizer China in Hangzhou with 2 x 2,000L disposable bioreactors, which will be expanded to 4 x 2,000L can. There are also two state-of-the-art production facilities for the manufacture of drugs (DP), the formulation of drugs and the filling into vials and syringes. Also in March 2021, the acquisition of CMAB, a contract development and production organization (CDMO) for biologics based in Suzhou, China, was announced . The CDMO plant maintains systems (MFG21 / DP11) with 7,000 liters of bioreactor DS capacity as well as a DP production facility for liquid and lyophilization filling. WuXi Biologics acquired 100% of the shares in CMAB, which is renamed WuXi Biologics (Suzhou) and operated as a wholly-owned subsidiary. It is expected that all of these acquired facilities will be ready for GMP production in 2021, expanding WuXi Biologics’ global footprint. With these expansions, the total capacity of the company’s 11 DS systems in China , the USA and Germany will be increased to 150,000 liters by the end of 2021. In addition, there will be nine GMP-DP vial and syringe lines in China , USA and Germany this year to meet all customer needs. Dr. Chris Chen , CEO of WuXi Biologics, commented, “We are pleased to have signed these significant contracts with Bayer, Pfizer and the CBC Group and welcome the highly skilled talent to our WuXi Biologics family. Over the past ten years, we have continued to expand our capacities and capabilities to build a global biologics network while strengthening the local supply chain to meet the growing biologics outsourcing requirements. With a total of 33 planned DS and DP systems in five countries around the world, we will continue to manufacture high-quality biologics and deliver them promptly worldwide for the benefit of patients thanks to our robust production capacities and resilient supply chains. “ WuXi Biologics, a Hong Kong-listed company, is a leading global open access technology platform for biologics. It provides complete solutions that enable organizations to research, develop, and manufacture biologics from concept to commercial manufacture. Ashish Nain

CMAB Biopharma Frequently Asked Questions (FAQ)

  • Where is CMAB Biopharma's headquarters?

    CMAB Biopharma's headquarters is located at Bld. C37, Suzhou.

  • What is CMAB Biopharma's latest funding round?

    CMAB Biopharma's latest funding round is Corporate Majority.

  • How much did CMAB Biopharma raise?

    CMAB Biopharma raised a total of $72M.

  • Who are the investors of CMAB Biopharma?

    Investors of CMAB Biopharma include WuXi Biologics, Juming Ventures, Qianhai Ark Asset Management, CBC Group, Cormorant Asset Management and 6 more.



CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.